Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.

Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of neoadjuvant followed by adjuvant immunotherapy-based regimens in patients with resectable NSCLC; Describe current evidence on the use of neoadjuvant plus adjuvant immunotherapy in patients with resectable NSCLC; and Outline practical strategies to integrate neoadjuvant plus adjuvant immunotherapy-based regimens into the treatment plan for appropriate patients with resectable NSCLC.

Please visit answersincme.com/TUD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the rationale for using novel add-on therapy in patients with pulmonary arterial hypertension (PAH) who are receiving stable background therapy, and the clinical implications of the latest evidence on these add-on therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of novel add-on therapies in patients with PAH who are receiving stable background therapy; Describe the latest clinical data for novel add-on therapies for patients with PAH who are on stable background therapy; and Outline multidisciplinary strategies for the optimal integration of novel add-on therapies into the existing treatment landscape for patients with PAH, as they become available.

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Please visit answersincme.com/NQF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses current guideline-supported best practices in the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids (OCS) in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/GSN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and thoracic surgery discuss chemo-immunotherapeutic approaches in early-stage non–small cell lung cancer. Upon completion of this activity, participants should be better able to: Review the clinical profiles of available and emerging neoadjuvant and perioperative immunotherapy-based approaches for patients with early-stage NSCLC; Identify patients for whom a neoadjuvant or perioperative immunotherapy-based approach is warranted, based on the available and emerging clinical data; and Outline a multidisciplinary strategy to improve outcomes in early-stage NSCLC through the use of neoadjuvant or perioperative immunotherapy-based approaches in appropriate patients.

Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/DDC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the current guidelines and evidence on the use of sequential combination therapy in patients with pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Review the current guideline recommendations on sequential combination therapy based on risk stratification in patients with pulmonary arterial hypertension (PAH); Discuss the biologic and clinical rationale for using guideline-recommended sequential combination therapy in patients with PAH; and Outline evidence-based, individualized strategies to optimize patient outcomes with sequential combination therapy in PAH.

Please visit answersincme.com/TJX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses low-density lipoprotein (LDL) receptor–independent therapies for homozygous familial hypercholesterolemia (HoFH) via two patient case studies. Upon completion of this activity, participants should be better able to: Identify patients with HoFH through differential diagnosis; Review the clinical profiles of novel strategies to reduce LDL cholesterol in patients with HoFH that work independently of LDL receptors; and Outline patient-centered strategies to maximize quality of life for patients with HoFH on lipid-lowering therapies.

Please visit answersincme.com/XTX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in cardiology discuss the diagnosis and management of homozygous familial hypercholesterolemia (HoFH). Upon completion of this activity, participants should be better able to: Describe the clinical impact of early and intensive treatment for patients with HoFH; Identify patients with HoFH through differential diagnosis; and Review the clinical profiles of novel strategies to reduce low-density lipoprotein (LDL).

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.

Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.

Please visit answersincme.com/PBR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in managing hypertrophic cardiomyopathy (HCM) discuss best practices for diagnosis and evidence-based strategies using cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Identify best practices to optimally diagnose patients with HCM in order to improve patient outcomes; Describe the clinical impact of cardiac myosin inhibitors in managing patients with obstructive HCM; and Outline practical strategies to incorporate cardiac myosin inhibitors into treatment plans for patients with obstructive HCM.

Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adjuvant chemotherapy for patients with early-stage non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for adjuvant immunotherapy in patients with early-stage non–small-cell lung cancer (NSCLC) following surgery and chemotherapy; Review the clinical profiles of approved and emerging adjuvant immunotherapy regimens in early-stage NSCLC; and Outline factors that optimize integration of adjuvant immunotherapy regimens for early-stage NSCLC into clinical practice.

Please visit answersincme.com/UPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in allergy and respiratory disease discuss patient-centered strategies to improve treatment of children with asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Please visit answersincme.com/XQE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in non–small-cell lung cancer (NSCLC) discuss perioperative immunotherapeutic approaches in patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Describe the rationale for perioperative immunotherapeutic approaches in patients with resectable NSCLC; Outline the clinical impact of perioperative immunotherapeutic approaches in patients with resectable NSCLC; and Identify practical strategies to optimize the care of patients with resectable NSCLC, based on the current and emerging clinical data.

Please visit answersincme.com/TSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the rationale, latest evidence, and practical considerations for adding a locoregional approach (eg, tumor-treating fields therapy, stereotactic body radiation therapy) to systemic immunotherapy for patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Outline the mechanisms of action of novel locoregional therapies and their combination with immunotherapies to treat advanced NSCLC; Describe the evidence on combining novel locoregional therapies with systemic; Immunotherapy for advanced NSCLC; and Identify practical patient-centered strategies for the evidence-based use of combined locoregional and systemic immunotherapy treatment in advanced NSCLC.

Please visit answersincme.com/REP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology and a patient advocate share their perspectives on the impact of social determinants of health on outcomes for patients with nonvalvular atrial fibrillation (NVAF) and strategies to optimize care for patients experiencing disparities. Upon completion of this activity, participants should be better able to: Recognize the impact of social determinants of health (SDOH) on cardiovascular disease outcomes, focusing on nonvalvular atrial fibrillation (NVAF); Describe patient-centered approaches to enhance the detection and assessment of adverse SDOH in patients with NVAF; and Outline community-based strategies to optimize care for patients with NVAF experiencing disparities.